Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Oral Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP)
2017-002541-29Phase 3Unknown
- Sponsor
- Clementia Pharmaceuticals Inc.
- Start
- Sep 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of palovarotene in fibrodysplasia ossificans progressiva (FOP) (2 arms), sponsored by Clementia Pharmaceuticals Inc. Primary endpoint: Annualized change in new heterotopic ossification volume over 24 months. Status: unknown.
02
Drugs
palovarotene
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on 2017-002541-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002541-29.